Ikeda Yoshifumi

Dr. Ikeda Yoshifumi

Saitama Medical Unversity International Medical Center
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Journal of Arrhythmia
Verified
Journal Article
Open access
KMKazuhisa Matsumoto
Kazuhisa Matsumoto
DKDaisuke Kawano
Daisuke Kawano
WSWataru Sasaki
Wataru Sasaki
NTNaomichi Tanaka
Naomichi Tanaka
MNMasataka Narita
Masataka Narita
KMKazuo Matsumoto
Kazuo Matsumoto
Background: Recently, a novel contact force (CF) sensing catheter with mesh‐shaped irrigation tip (TactiFlex SE, Abbott) was invented and is expected to be useful for safe and effective radiofrequency ablation. However, this catheter's detailed characteristics of the lesion formation are unknown.Methods: With an in vitro model, TactiFlex SE and its predecessor, FlexAbility SE, were used. A cross‐sectional analysis of 60 s lesions (combination of various energy power settings [30, 40, and 50 W], and CFs [10, 30, and 50 g]) and longitudinal analysis (combination of various powers [40 or 50 W], CFs [10, 30, and 50 g] and ablation times [10, 20, 30, 40, 50, and 60 s]) of both catheters were analyzed and compared.Results: One hundred eighty RF lesions were created in protocol 1 and 300 in protocol 2. The lesion formation, impedance changes, and steam pops characteristics were similar between the two catheters. Higher CFs were related to higher incidences of steam pops. A nonlinear, time‐dependent increase in the lesion depth and diameter was observed for all power and CF settings, and linear, positive correlations between the RF delivery time and lesion volume were observed for all power settings. Compared with 40 W, a 50 W ablation created greater lesions. Longer durations with higher CF settings had a higher steam pop incidence.Conclusions: The lesion formation and incidence of steam pops with TactiFlex SE and FlexAbility SE were similar. A 40 or 50 W ablation with careful CF control not to exceed 30 g in addition to monitoring impedance drops was required to safely create transmural lesions.

20 June 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
TNTakahiko Nagase
Takahiko Nagase
SASo Asano
So Asano
MYMidori Yukino
Midori Yukino
HMHitoshi Mori
Hitoshi Mori
KGKoji Goto
Koji Goto
KMKazuo Matsumoto
Kazuo Matsumoto

1 June 2007 in Transplant International
Verified
Journal Article
Closed access
PDF file
IYIkeda Yoshifumi
Ikeda Yoshifumi
GTGero Tenderich
Gero Tenderich
AZArmin Zittermann
Armin Zittermann
KMKazutomo Minami
Kazutomo Minami
RKReiner Koerfer
Reiner Koerfer
Heart transplantation is the most effective therapy for end-stage heart failure in patients with diabetes mellitus (DM). However, diabetes-related complications (DRCs) are a relative contraindication for heart transplantation. Nevertheless, the increasing prevalence of both DM and congestive heart failure makes it necessary to perform heart transplantation even in those patients with advanced DM. We performed a retrospective analysis on long-term survival in 47 patients with insulin-treated DM and DRCs (group 1). Survival rate and causes of death were compared with data of a group of heart transplant recipients without DM (n = 1061, group 2). Mean follow-up time of all heart transplant recipients was 68.2 months (range: 0-204 months). Overall mortality during follow-up was 42.9%. Long-term survival did not differ significantly between study groups, but tended to be shorter in group 1 than in group 2 (P = 0.07). In group 1, steroid-free immunosuppressive therapy was associated with a higher percentage of long-term survivors compared with no steroid-free immunosuppression. Our data demonstrate that long-term survival is acceptable in heart transplant recipients with preoperatively diagnosed DM and DRCs. Consequently, advanced DM should no longer be a relative contraindication for heart transplantation.

19 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IYIkeda Yoshifumi
Ikeda Yoshifumi
KTKenta Tsutsui
Kenta Tsutsui
YYYoshihiro Yamada
Yoshihiro Yamada
RKRitsushi Kato
Ritsushi Kato
TMToshihiro Muramatsu
Toshihiro Muramatsu
Takaaki SenbonmatsuTakaaki Senbonmatsu
Takaaki Senbonmatsu
The (pro)renin receptor ((P)RR), which evokes renin activity with prorenin, is secreted extracellularly as soluble (P)RR (s(P)RR) and may participate in tissue renin-angiotensin system (RAS) activity in severe heart failure (HF) patients. The aim of this study was to determine whether s(P)RR is an adequate marker in severe HF patients treated with RAS inhibitors, beta-blockers, and tolvaptan. We enrolled 11 patients with severe HF between May 2013 and June 2014. First of all, furosemide of all patients was changed to tolvaptan with hydrochlorothiazide and then the treatment had been changed according to the patient’s condition. After 1, 3, 6, and 12 months, the variance of s(P)RR, plasma renin activity (PRA), plasma renin concentration (PRC), brain natriuretic peptide (BNP) and their association was investigated. Furosemide was restarted in five patients and two patients suffered cardiac death. PRA/PRC and s(P)RR were unchanged (PRA: 10.7 ± 13.9 to 12.8 ± 8.5 ng/mL/h; PRC: 347.1 ± 577.5 to 148.3 ± 123.8 pg/mL; s(P)RR: 28.2 ± 19.3 to 33.4 ± 22.4 ng/mL) and had no significant correlations (PRA and s(P)RR: p = 0.36; PRC and s(P)RR: p = 0.35). There was a significant positive correlation with a high correlation coefficient (CC) between PRA and PRC (p < 0.0001, CC = 0.76), and a negative correlation with weak CC between BNP and s(P)RR (p = 0.01, CC = −0.45). In conclusion, s(P)RR was always high and had no correlations with disease state and PRA/PRC in severe HF patients.

14 May 2024 in HeartRhythm Case Reports
Verified
Journal Article
Open access
MNMasataka Narita
Masataka Narita
IYIkeda Yoshifumi
Ikeda Yoshifumi
KMKazuhisa Matsumoto
Kazuhisa Matsumoto
HMHitoshi Mori
Hitoshi Mori
KTKenta Tsutsui
Kenta Tsutsui
RKRitsushi Kato
Ritsushi Kato

19 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IYIkeda Yoshifumi
Ikeda Yoshifumi
RKRitsushi Kato
Ritsushi Kato
HMHitoshi Mori
Hitoshi Mori
KTKenta Tsutsui
Kenta Tsutsui
KMKazuhisa Matsumoto
Kazuhisa Matsumoto
KMKazuo Matsumoto
Kazuo Matsumoto
Background: The prognosis of acute decompensated heart failure (ADHF) and heart failure (HF) with atrial fibrillation (AF) has been dismal. This study was performed to investigate the clinical outcomes of catheter ablation (CA) performed in patients with concurrent ADHF and AF. Methods: We retrospectively analyzed ADHF patients with AF who were admitted to our institution from 2007 to 2017. Results: In total, 472 patients were included in this study, with a mean follow-up duration of 32.8 ± 32.9 months. The 5-year event-free rate (cardiovascular death and HF hospitalization) was 61.4%, and the 10-year event-free rate was 42.7%. A comparative analysis of the event group and control group revealed that patients in the event group were older (event group vs. control group: 72.1 ± 11.0 vs. 68.8 ± 13.4 years, p = 0.008) and had a higher proportion of Clinical Scenario 3 classifications (event group vs. control group: 24% vs. 12%, p = 0.001). Notably, patients in the event group had a lower sinus rhythm maintenance rate (event group vs. control group: 17% vs. 31%, p < 0.001) and CA rate (event group vs. control group: 9% vs. 21%, p = 0.003). The CA group had a higher event-free rate than the non-CA group, and this trend persisted even after matching the patients’ backgrounds (log-rank test: p < 0.001). Conclusions: Patients presenting with AF at the onset of ADHF showed a poor prognosis, whereas CA demonstrated potential for improving the prognosis for some of these patients.